Boston Scientific Corporation
BSX
$51.12
$0.661.31%
NYSE
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 4.59% | -1.57% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.59% | -1.57% | |||
| Cost of Revenue | 0.25% | -0.74% | |||
| Gross Profit | 6.53% | -1.93% | |||
| SG&A Expenses | 1.24% | -2.89% | |||
| Depreciation & Amortization | 0.43% | 1.75% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.57% | -2.69% | |||
| Operating Income | 16.23% | 2.98% | |||
| Income Before Tax | -8.86% | 66.14% | |||
| Income Tax Expenses | 188.07% | -686.67% | |||
| Earnings from Continuing Operations | -32.41% | 99.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 0.00% | 0.00% | |||
| Net Income | -32.36% | 99.55% | |||
| EBIT | 16.23% | 2.98% | |||
| EBITDA | 12.51% | 1.21% | |||
| EPS Basic | -31.69% | 99.27% | |||
| Normalized Basic EPS | 15.22% | -1.03% | |||
| EPS Diluted | -32.22% | 99.96% | |||
| Normalized Diluted EPS | 15.63% | -0.83% | |||
| Average Basic Shares Outstanding | -0.99% | 0.15% | |||
| Average Diluted Shares Outstanding | -1.35% | -0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||